ReviewClinical reviews in allergy & immunology2009
Vascular disease in scleroderma.
Review in Clinical reviews in allergy & immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 124 citations in OpenAlex.
- Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.Annals of the rheumatic diseases · 2011Trial
- Micro- and Macro-Vascular Disease in Systemic Sclerosis and Very Early SSc (VEDOSS): Results from a Monocentric Observational Study.Biomedicines · 2026Article
- ERG Regulates Lymphatic Vessel Specification Genes and Its Deficiency Impairs Wound Healing-Associated Lymphangiogenesis.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
- Incidence of Systemic Vasculitis and Clinical Outcomes in Systemic Sclerosis: 2-Years Follow-Up of Asymptomatic Positive for Anti-Neutrophilic Cytoplasmic Antibody.Clinical, cosmetic and investigational dermatology · 2024Article
- Expression and correlation of the Pi3k/Akt pathway and VEGF in oral submucous fibrosis.Cell proliferation · 2023Article
- Real life use of prostacyclin analog (iloprost), a multi-centric survey data from the Scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature.Acta bio-medica : Atenei Parmensis · 2023Review
- Brachial artery flow-mediated dilation in patients with systemic sclerosis: an experience from tertiary care center from North India.Clinical rheumatology · 2023Article
- High-resolution Doppler ultrasound in systemic sclerosis: Analysis of digital arteries and nailfold microvasculature using 18-5 MHz and 33-9 MHz probes.International journal of rheumatic diseases · 2022Article
- Esophageal Dysfunction in Systemic Sclerosis: An Update.Rheumatology and therapy · 2021Review
- Infections of scleroderma digital ulcers: A single center cohort retrospective study.Dermatology reports · 2021Article
- Endothelial-to-mesenchymal transition in systemic sclerosis.Clinical and experimental immunology · 2021Review
- The anti-aging protein alpha-Klotho in systemic sclerosis patients: does a relationship to telangiectasia exist?Zeitschrift fur Rheumatologie · 2020Article
- Short course of simvastatin has no effect on markers of endothelial activation in normolipidemic patients with systemic sclerosis.The Journal of international medical research · 2018Article
- Impairment of microcirculation and vascular responsiveness in adolescents with primary Raynaud phenomenon.Pediatric rheumatology online journal · 2018Article
- Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin.Frontiers in immunology · 2018Article
- Agonistic Anti-PDGF Receptor Autoantibodies from Patients with Systemic Sclerosis Impact Human Pulmonary Artery Smooth Muscle Cells FunctionFrontiers in immunology · 2017Article
- Thrombotic complications after radial arterial line placement in systemic sclerosis: A case series.Seminars in arthritis and rheumatism · 2016Article
- Vascular Remodelling and Mesenchymal Transition in Systemic Sclerosis.Stem cells international · 2016Review
- T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review.Clinical reviews in allergy & immunology · 2015Review
- Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction.Clinical rheumatology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although scleroderma is generally considered a fibrosing disease of the tissues, it is now recognized that the underlying vascular disease is playing a fundamental role in its pathogenesis and associated tissue injury. The exact mechanism for the widespread scleroderma vascular disease is still unknown, but endothelial cell injury induced by infection, immune-mediated cytotoxicity, antiendothelial antibodies, and/or ischemia-reperfusion have all been implicated. The downstream effects of blood vessel perturbation produce "biomarkers" of vascular damage that reflect disease and may predict clinical outcomes. A complex interaction between endothelial cells, smooth muscle cells, extracellular matrix, and intravascular circulating factors is now recognized to contribute to the vascular reactivity, remodeling, and occlusive disease of scleroderma. Understanding the mechanisms underlying these processes provides rationale of novel therapeutic strategies and specific targeted therapy. This review will outline some of the evidence for the causes and consequences of scleroderma vascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.